IMMUNEX CORPORATION v. SANDOZ INC.

CourtDistrict Court, D. New Jersey
DecidedJuly 23, 2021
Docket2:16-cv-01118
StatusUnknown

This text of IMMUNEX CORPORATION v. SANDOZ INC. (IMMUNEX CORPORATION v. SANDOZ INC.) is published on Counsel Stack Legal Research, covering District Court, D. New Jersey primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
IMMUNEX CORPORATION v. SANDOZ INC., (D.N.J. 2021).

Opinion

UNITED STATES DISTRICT COURT DISTRICT OF NEW JERSEY _________________________________________

IMMUNEX CORPORATION, AMGEN MANUFACTURING, LIMITED and HOFFMAN LA-ROCHE INC., Civil Action No. 16-1118 (CCC)

Plaintiffs, CLERK’S OPINION GRANTING IN PART v. AND DENYING IN PART PLAINTIFFS’ MOTION SANDOZ, INC., SANDOZ INTERNATIONAL TO TAX COSTS GMBH and SANDOZ GMBH,

Defendants.

This matter has come before the Clerk on the motion [Dkt. Entry 750] of Plaintiffs

Immunex Corporation (“Immunex”) and Amgen Manufacturing, Limited (“Amgen”)

(together, “Plaintiffs”) to tax costs against Defendants Sandoz, Inc., Sandoz International

GmbH and Sandoz GmbH (collectively, “Defendants”), pursuant to Federal Rule of Civil

Procedure 54(d) and Local Civil Rule 54.1. Defendants oppose this motion.

As the parties are well-aware of the factual and procedural histories of this patent

infringement suit, the Clerk presents herein a very cryptic summary, as is necessary to address

the motion at hand.

Plaintiffs and Hoffman La-Roche Inc. (“Roche”) instituted suit on February 26, 2016

[Dkt. Entry 1], alleging patent infringement by Defendants, under 35 U.S.C. § 271, including

§ 271(e)(2)(C), part of the Biologics Price Competition and Innovation Act (“the BPCIA”).

Relevant to this matter, the BPCIA allows for the submission of an abbreviated Biologics

License Application (“aBLA”), seeking FDA authorization to market a biosimilar version

of an approved biologic drug, such as that at issue in this litigation. The five patents-in-suit covered etanercept, the active ingredient of the biologic drug

product, ENBREL®: United States Patent Nos. 8,063,182 (“the ’182 patent”), 8,163,522 (“the

’522 patent”), 7,915,225 (“the ’225 patent”), 8,119,605 (“the ’605 patent”), and 8,722,631 (“the

’631 patent”). Immunex is the exclusive licensee of all commercial rights in the ’182 and ’522

patents, owned by Roche, and is the owner of the ’225, ’605, and ’631 patents. Immunex has

granted Amgen an exclusive license/sublicense to the asserted patents.

Defendant Sandoz, Inc. is the United States agent for co-defendants, Sandoz International

GmbH and Sandoz GmbH, German and Austrian corporations, respectively, for the purpose

of filing regulatory submissions with the Food and Drug Administration (“FDA”). On

September 29, 2015, the FDA accepted Defendants’ aBLA, seeking to market a biosimilar

version of Immunex’s ENBREL®. In their complaint, Plaintiffs and Roche asserted that

Defendants committed an act of infringement under 35 U.S.C. § 271(e)(2)(C) when they caused

Sandoz Inc. to submit Defendants’ aBLA, seeking FDA approval to commercially manufacture,

use, offer for sale, sell, distribute in, or import into the United States, Defendants’ etanercept

product prior to the expiration of the asserted patents.

Because Sandoz Inc. could neither accept nor waive service of process on behalf

of its Austrian and German co-defendants, those two entities were served pursuant to the

procedures authorized by the Court’s Order of June 14, 2016 [Dkt. Entry 65], granting Plaintiffs’

unopposed motion pursuant to Federal Rule of Civil Procedure 4(f) [Dkt. Entries 58, 64]. That

is, the Court issued Letters Rogatory to the appropriate Judicial Authority of Austria (a non-

signatory to the Hague Convention), requesting international assistance to serve the complaint

and summons on Sandoz GmbH, and entered an Order appointing Crowe Foreign Services as

-2- the authority to forward to the Central Authority in Germany (a signatory to the Hague

Convention, like the United States) the papers to be served in this case, in order to effect service

on Sandoz International GmbH.

Pretrial proceedings occurred, with a Markman hearing on February 15, 2017 [Dkt. Entry

146], summary judgment motions by Plaintiffs in September 2017 [Dkt. Entries 221, 225], status

conferences in March and April 2018 [Dkt. Entries 421, 423, 424, 425, 444], and in limine

motions by both sides in June 2018 [Dkt. Entries 512-521].

On June 7, 2018, the Court entered an Amended Consent Preliminary Injunction [Dkt.

Entry 509], limiting Defendants’ activities regarding its etanercept product. Pursuant to a

stipulation [Dkt. Entry 510] entered that day, the asserted claims of infringement of the ‘225,

‘605 and ‘631 patents were dismissed with prejudice.

By Order entered on September 10, 2018 (“Stipulation of Infringement”) [Dkt. Entry

619], Defendants stipulated to infringement of claims 11-12 and 35-36 of the ‘182 patent, and

claims 3, 8 and 10 of the ‘522 patents, then still at issue.

A 10-day bench trial on the validity of the ‘182 and ‘522 patents took place on September

11-14, 17, 18, 20, 21, 24 and 25, 2018. [Dkt. Entries 621, 622, 627, 629-35]. The parties

submitted post-trial briefing, including proposed findings of fact and conclusions of law [Dkt.

Entries 645-53], and presented closing arguments on November 19, 2018 [Dkt. Entry 656].

On August 9, 2019, the Court entered its opinion and order [Dkt. Entries 689, 690],

finding no invalidity of the ‘182 and ‘522 patents, that Defendants infringed the asserted

claims of those two patents, pursuant to the September 2018 Stipulation of Infringement, and

that the parties remained bound by the terms of the Amended Consent Preliminary Injunction.

-3- On October 7, 2019, the Court entered a Stipulated Permanent Injunction [Dkt. Entry

718], enjoining Defendants, and all related individuals and entities, from making, using, offering

to sell, or selling within the United States, or importing into the United States, any product

containing etanercept until the later of the expiration of any infringed and valid claim of the ‘182

patent on November 22, 2028, or any infringed and valid claim of the ‘522 patent on April 24,

2029.

The Court entered its Final Judgment and Order of Permanent Injunction [Dkt. Entry

719] in favor of Plaintiffs and Roche, and against Defendants, on October 8, 2019, and on that

day, Defendants filed their notice of appeal to the Court of Appeals for the Federal Circuit [Dkt.

Entry 720].

By letter order of October 22, 2019 [Dkt. Entry 732], the Court granted all parties’

requests to extend the time in which to file taxation and attorney’s fees motions, until 30 days

after the issuance of the Federal Circuit’s mandate.

The Federal Circuit affirmed this Court’s final judgment on July 1, 2020 [Dkt. Entries

745, 746] and denied Defendants’ petition for en banc rehearing, on September 29, 2020 [Dkt.

Entry 748]. Its mandate issued on October 6, 2020 [Dkt. Entry 749], and accordingly, within

30 days thereafter, on November 5, 2020, Plaintiffs filed their taxation motion [Dkt. Entry 750],

now before the Clerk.

Plaintiffs initially sought a total of $408,749.87 in their bill of costs, AO 133 form

[Dkt. Entry 750-2], but decreased their request, in response to Defendants’ brief in opposition

(“Defs.’ Opp.”). Pursuant to their updated bill of costs [Dkt. Entry 755-1], they seek a total

of $368,382.46, comprised of the fees of: the clerk ($400.00); the marshal ($61,680.00);

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Louisiana Power & Light Co. v. Kellstrom
50 F.3d 319 (Fifth Circuit, 1995)
Hurtado v. United States
410 U.S. 578 (Supreme Court, 1973)
Crawford Fitting Co. v. J. T. Gibbons, Inc.
482 U.S. 437 (Supreme Court, 1987)
Farrar v. Hobby
506 U.S. 103 (Supreme Court, 1992)
Hairline Creations, Inc. v. Diane Kefalas
664 F.2d 652 (Seventh Circuit, 1981)
James T. Crues v. Kfc Corporation
768 F.2d 230 (Eighth Circuit, 1985)
Cheryle A. Collins and Heywood Fuller T. v. Kay Gorman
96 F.3d 1057 (Seventh Circuit, 1996)
Taniguchi v. Kan Pacific Saipan, Ltd.
132 S. Ct. 1997 (Supreme Court, 2012)
Reger v. THE NEMOURS FOUNDATION, INC.
599 F.3d 285 (Third Circuit, 2010)
Bollitier v. International Brotherhood of Teamsters
735 F. Supp. 623 (D. New Jersey, 1989)
Lazaridis v. Wehmer
591 F.3d 666 (Third Circuit, 2010)
Garonzik v. Whitman Diner
910 F. Supp. 167 (D. New Jersey, 1995)
Law Office G.A. Lambert and Associates v. Davidoff
72 F. Supp. 3d 110 (District of Columbia, 2014)
Manildra Milling Corp. v. Ogilvie Mills, Inc.
76 F.3d 1178 (Federal Circuit, 1996)
Arrambide v. Wal-Mart Stores, Inc.
33 F. App'x 199 (Sixth Circuit, 2002)

Cite This Page — Counsel Stack

Bluebook (online)
IMMUNEX CORPORATION v. SANDOZ INC., Counsel Stack Legal Research, https://law.counselstack.com/opinion/immunex-corporation-v-sandoz-inc-njd-2021.